Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer

The study included patients with inoperable stage III or IV ovarian cancer who were initially treated in FIGO stage III or IV. "A phase II trial to explore the efficacy and safety of neoadjuvant chemotherapy plus propranolol in patients with histologically confirmed high-grade serous ovarian cancer." Na row standard subjects were divided into 2 groups: Queue A accept propranolol hydrochloride (20 mg, twice daily), paclitaxel liposomes (135-175 mg/m² on day 1, every 3 weeks), and carboplatin (AUC = 4-5, on day 1, every 3 weeks) were administered as neoadjuvant therapy for a total of 3 cycles, followed by intermittent debulking surgery (IDS). Propranolol hydrochloride was initiated upon definitive pathology and continued until day 14 of the third cycle, with subsequent dose reductions: first by 50% for at least 3 days, then by another 25% for at least 3 days, before complete discontinuation. Queue B receive paclitaxel liposome (135-175 mg/m2, d1, Q3W) and carboplatin (AUC = 4-5, d1, Q3W), neoadjuvant therapy cycle, a total of 3 line then intermittent tumor cells to destroy the loss (interval debulking surgery, IDS); Patients will accept the tumor assessment before the surgery, postoperative by researchers according to aid in the treatment of ovarian cancer guidelines take corresponding.